Printer Friendly

Red blood cell concentrate transfusion strategies utilised at a tertiary-level paediatric intensive care unit: A descriptive study on impact and cost.

Anaemia, which refers to a blood haemoglobin level that is two standard deviations below the median age-dependent reference, is commonly seen in critically ill patients. It may be due to the underlying disease or treatment causing bone marrow suppression, overt or occult blood loss, inadequate erythropoietin response or nutritional deficiencies. [1] Red blood cell (RBC) transfusions are aimed at increasing the haemoglobin concentration and hence increasing the cells' capacity for carrying and delivering oxygen to tissue. [2] For patients not in an intensive care unit (ICU), the World Health Organization (WHO) defines a haemoglobin level <4 g/dL and 4-6 g/dL as the cut-off for profound and severe anaemia, respectively.

Outcomes following severe anaemia are unsatisfactory, with an in-hospital mortality rate of 9-10% being reported, and a 6-month mortality rate of 12%. [3] WHO guidelines encourage the rational use of blood transfusion to preserve this scarce resource and to reduce the risk of transfusion-transmitted infections, [4] and advocate paediatric blood transfusion to be reserved for children with a haemoglobin level <4 g/dL (or <6 g/dL if accompanied by complications). The haemoglobin threshold for RBC transfusion among septic patients is <7 g/dL. [5, 6] The optimal haemoglobin threshold for blood transfusion in critically ill children remains uncertain. [7]

Up to 50% of all critically ill children admitted to a paediatric intensive care unit (PICU) will receive one or more RBC transfusions during their stay, increasing to 75% for children whose stay exceeds 7 days. [7-9] There are limited published data on the decision tree guiding the paediatric intensivist to prescribe an RBC transfusion. [10] In 2007, the Transfusion Strategies for Patients in Paediatric Intensive Care Units (TRIPICU) group suggested a haemoglobin threshold of <7 g/dL rather than <9.5 g/dL for prestored leukocyte-reduced RBC transfusion in stable critically ill children, as this would decrease mortality without increasing adverse outcomes and would reduce the requirement for RBC transfusions. [2] This recommendation was supported by the guidelines of the American Association of Blood Banks. However, practising physicians suggested a haemoglobin threshold of 7-8 g/dL as a trigger for transfusion, as there is no difference in mortality and length of hospital stay in adult patients when these levels are used. [11] This recommendation was unusual, given the increased vulnerability of adult patients to adverse effects from the use of leukocyte-replete RBC transfusion, which is known to generate cytokines and activate an inflammatory response. [7] Other adverse effects, including transfusion-associated lung injury, infections and transfusion reactions have been described among ICU patients who received RBC transfusions. [1, 8, 12, 13]

Against this background, and considering the high cost of transfusions and the limited and erratic supply of blood products in Africa, [14] we undertook a retrospective chart review to describe the outcomes and costs associated with different transfusion strategies used to treat critically ill anaemic children in a PICU.



The PICU at the Inkosi Albert Luthuli Central Hospital in Durban, South Africa (SA), is a multidisciplinary public-sector tertiary-level unit that serves a population of approximately 3 million children under the age of 12 years. The unit has 14 beds and admits approximately 500-600 children annually. Approximately 80% of admissions are due to emergencies, mostly (75%) as a result of medical conditions.

Study population

Records of RBC concentrate transfusions at the PICU during 2015 (1 January to 31 December) were obtained from the South African National Blood Service. To decide which cases to include in the study, electronic clinical records were reviewed according to predefined criteria based on the guidelines formulated by the TRIPICU study group. [7] Patients were excluded from the study if:

* post conception age was <40 weeks

* the patient weighed <3 kg

* the patient was younger than 3 days or older than 12 years

* a decision to withhold or withdraw critical care was noted

* a blood exchange transfusion had been performed

* the patient was discharged <24 hours post transfusion

* acute blood loss was noted.

Cases were grouped according to whether the transfusion strategy was defined as restrictive, 'modified liberal' or mixed. Patients who received an RBC concentrate transfusion at a haemoglobin level [less than or equal to] 7.0 g/dL were assigned to the restrictive group, whereas those who had received a transfusion at a haemoglobin level >7 g/dL were assigned to the 'modified liberal' group. The mixed group was made up of patients who had received multiple RBC concentrate transfusions, adopting a restrictive strategy on one occasion and a modified liberal strategy in another.

The classification 'modified liberal' was used to differentiate this strategy from the liberal strategy used in the TRIPICU study, for which a haemoglobin level [greater than or equal to] 9.5 g/dL was used as cut-off. [7] In our study, the 'modified liberal' group was further subdivided based on haemodynamic stability at the point of transfusion. Haemodynamic instability was defined as any occurrence of hypotension or an increase in the use of inotropic support 24 hours prior to transfusion, whereas haemodynamically stable patients lacked these features. These definitions were modified from the TRIPICU study [7] because of the retrospective nature of this review.

Demographic data, including age, gender, HIV status and primary and secondary diagnoses, were extracted from the electronic records of all the included cases. The severity of a patient's illness was defined according to the Paediatric Index of Mortality (PIM) 3 score at admission.

To evaluate adverse effects of RBC transfusions, vital signs and markers for sepsis and organ dysfunction as defined by the guidelines for surviving sepsis, were evaluated 24 hours before and 3 days after the transfusion. [2] The number of days on intermittent positive-pressure ventilation (IPPV), length of PICU stay and mortality were considered in assessing the outcome associated with the different transfusion strategies. Both the cost of the RBC concentrate, according to transfusion strategy, and the levies associated with the transfusion were taken into account to evaluate the cost of an RBC transfusion. Factors considered to affect levies included the number of afterhours transfusions, the number of emergency and standard cross-matches performed, and the need for typing and screening. Afterhours transfusion levies are charged for any transfusion-related activity performed between 18:00 and 08:00 on weekdays and over weekends (between 18:00 on a Friday and 08:00 on a Saturday and between 13:00 on a Saturday and 08:00 on a Monday).

Statistical analysis

The four study groups were compared with regard to proportions and frequencies. Proportions were compared using chi-squared tests. Statistical significance was set at p<0.05.

Ethical approval

Approval for the study was obtained from the biomedical research ethics committee of the University of KwaZulu-Natal (ref. no. BE495/16) and the South African National Blood Service. As this was a retrospective study, informed consent was not obtained from patients.


Of the 556 patients admitted to the unit in 2015, 203 (36.5%) received a blood transfusion. The inclusion criteria were met in 118 of these cases (Fig. 1) and a total of 183 transfusions were performed. Of the included cases, 27 were classified as having had a restrictive transfusion strategy and 68 were assigned to the 'modified liberal' group. A mixed strategy was adopted in 23 of the included cases. In the 'modified liberal' group, 47 cases were haemodynamically stable and 21 were haemodynamically unstable. As shown in Fig. 1, cases were excluded mainly because patients weighed <3 kg (n=46) or had suffered acute blood loss (n=26).

Baseline characteristics

There were no significant differences in baseline characteristics (demographics, PIM score, number of transfusions and diagnoses) between the restrictive and 'modified liberal' (haemodynamically stable and unstable) groups (Table 1). Some patients in the 'modified liberal' group had more than one RBC transfusion and their haemodynamic status varied during the different RBC concentrate transfusions. The prevalence of HIV infection and the number of RBC transfusions were significantly higher among patients with a mixed transfusion strategy than among those in the other groups.

Immediate effects post transfusion

Physiological effects post transfusion are shown in Table 2. For these analyses, transfusions previously categorised as mixed were reclassified as either restrictive (n=64) or modified liberal (n=119). There were no significant differences in physiological parameters between the restrictive and modified liberal strategies post transfusion.

Clinical outcomes associated with different transfusion strategies

As shown in Table 3, the modified liberal transfusion strategy was associated with a higher mortality rate (27.9%) than the restrictive (11.1%) strategy. Similarly, a higher mortality rate was seen in the haemodynamically unstable (42.9%) group than in the stable group (21.3%). There was no statistically significant difference in the mortality rate between patients in the restrictive and haemodynamically stable groups (p=0.3), but a statistical difference in mortality was found when the restrictive and haemodynamically unstable cases were compared (p=0.03). There was no statistical difference in the duration of IPPV or length of ICU stay between the restrictive strategy and any of the subgroups of the modified liberal strategy. Patients in the mixed transfusion group had the worst outcomes across all the clinical parameters.

Costs related to transfusion

The cost of a paediatric RBC concentrate pack was R1 485.65 in 2015. The 74 transfusion units used for the restrictive group amounted to a total cost of R119 065.94, while the 132 transfusion units used in the 'modified liberal' group amounted to R225 428.61 (Table 4A). If a restrictive strategy had been used for the haemodynamically stable patients in the modified liberal group, a cost saving of R155 280.15 would have been realised. This decision would not have increased the risk of mortality or prolonged ICU stay.

The levies associated with a transfusion, and the consequent effect of the transfusion strategy and decision on the cost of a transfusion, are shown in Table 4B. Of the total number of transfusions, 74 (40.4%) were unnecessarily performed after hours, which resulted in an additional cost of R26 746.50 for after-hours transfusion levies and another R2 242.17 for unnecessary after-hours typing and screening.


Our findings support the implementation of a restrictive strategy for RBC transfusions, as patients in this group had the lowest mortality rate and did not show an increased need for intensive care. Although mortality rates cannot strictly be compared among the three strategies in a retrospective chart review, the similarities in demographic data, primary and secondary diagnoses and severity of disease seen among these groups allow for cautious comparisons. Differences in haemodynamic stability may have led to haemodynamically stable patients in the modified liberal group having better outcomes, similar to those in the restrictive group, whereas outcomes for haemodynamically unstable patients in this group tended towards those associated with the mixed group. Studies among larger randomised paediatric and neonatal critical care populations have yielded similar findings, with restrictive transfusion strategies reducing the need for transfusion without increasing morbidity or mortality. [7, 15] Over 30 randomised trials across more than 12 000 adult patients have consistently shown that a restrictive transfusion strategy (with haemoglobin levels at [less than or equal to] 7 g/dL) does not adversely affect clinical outcome. [16] Similar to the findings of our study, the TRIPICU study--the only robust trial in children--has not shown any differences in mortality or multiple organ dysfunction syndromes between patients for whom a restrictive strategy was adopted and haemodynamically stable patients when a more liberal strategy was used. [17] The TRIPICU study further recommends a restrictive transfusion strategy for stable PICU patients, but not for premature infants, older children, patients with coronary artery disease, or children with severe hypoxaemia, haemodynamic instability, active blood loss or cyanotic heart disease. [7] In children with more severe illness or for those in specific subpopulations, such as recovering after cardiac surgery, transfusions were initiated at higher haemoglobin levels. [10]

Our study further also highlighted the considerable cost associated with RBC transfusions. In a retrospective descriptive study from Mexico, Cazares-Benito et al. [18] concluded that the use of blood transfusion in cases not indicated by the guidelines of the American Association of Blood Banks impacted notably on total health cost. Blood products for transfusion are often in short supply and constitute a large part of a hospital's medicine budget. High usage puts a considerable financial burden on resource-limited institutions. Adopting a restrictive transfusion strategy may reduce the demand for blood transfusion, and so help to manage associated costs. In a study among patients with septic shock, randomised to receive RBC transfusions at either a low or a high haemoglobin threshold, a median of 1 unit of blood was saved in the low-threshold group for a median of every 4 units utilised. [5] It is not clear exactly how many RBC transfusions could have been saved in our study had a restrictive strategy been implemented, but a study from elsewhere in SA showed that implementing a restrictive transfusion strategy exclusively resulted in half the number of RBC transfusions being performed, with considerable cost savings reported. [19] Implementing a restrictive transfusion strategy may decrease the overuse of RBC transfusions, thereby reducing the associated risks and costs. [20]

Another-cost saving strategy could be to enforce a daytime transfusion policy, which would eliminate paying levies for afterhours transfusions. It is possible that institutions fail to implement a daytime transfusion policy because of a lack of awareness of the financial implications of an after-hours transfusion practice and the associated delivery and retrieval processes among staff. Unavoidable levies such as for emergency cross-matches should be restricted, as blood can often be obtained within 45 minutes with routine services. Blood typing and screening should be severely restricted as it does little to save time if blood is required. The use of an audit form to monitor all decisions related to the use of blood products is recommended, as this has been shown to reduce the need for RBC transfusions and associated costs effectively. [21]

Another important finding of this study was the lack of any serious physiological variance between the pre- and posttransfusion parameters for the restrictive or the modified liberal transfusion groups. This suggests that the haemoglobin cut-off level, the haemodynamic stability, the primary and secondary diagnoses and the severity of illness at transfusion were not affected by the transfusion process. All transfusions were leucocyte depleted, which may account for the lack of acute transfusion-related lung injury, multi-organ dysfunction, cardiac overload and nosocomial infections. Three studies from Kenya have shown that severe anaemia can be dangerous in the hospitalised paediatric population, as mortality rates were significantly higher in patients with haemoglobin levels <5 g/dL. The risk of mortality decreased with receipt of RBC transfusions. [6, 22, 23]

Study limitations

There were several limitations in this study. This was a singlecentre, retrospective study, with some missing data and a smaller sample size than what was used in the TRIPICU study, which limits its external validity Defining the severity of subjects' illness was challenging and our definition of haemodynamic stability did not match that of the TRIPICU study, nor was a distinction made between cyanotic or acyanotic cardiac lesions. In addition, the transfusion service was used as a primary source for patient recruitment. However, the study yielded useful results overall, as it was performed in a large tertiary centre and analysed transfusion parameters over a 1-year period.


It could be prudent to adopt a restrictive RBC transfusion strategy in a PICU. Such a change is unlikely to increase mortality risk, the need for mechanical ventilation or ICU stay, and could reduce a unit's operating cost with regard to transfusions. Our unit has since adopted this strategy. A prospective randomised study to compare the effects of transfusing at different predefined haemoglobin cut-off levels in critically ill children is still required.

Acknowledgements. We would like to thank the chief executive office at Inkosi Albert Luthuli Central Hospital for permission to conduct the study, the staff of ICU4 for caring for the enrolled patients, and the South African National Blood Service for allowing access to their database. We thank Ms Catherine Connolly, biostatistician in the Discipline of Public Health Medicine, University of KwaZulu-Natal, for her assistance with statistical analysis.

Author contributions. PBSR designed the study, collected data and wrote the manuscript. PMJ acted as supervisor and assisted in refining the design, data analysis and interpretation, and revising earlier drafts of the manuscript.

Funding. None.

Conflicts of interest. None.

[1.] Bateman ST, Lacroix J, Boven K, et al. Anemia, blood loss, and blood transfusions in North American children in the intensive care unit. Am J Respir Crit Care Med 2008;178(1):26-33.

[2.] Demaret P, Tucci M, Ducruet T, Trottier H, Lacroix J. Red blood cell transfusion in critically ill children. Transfusion 2014;54:365-375. trf.12261

[3.] Brabin BJ, Premji Z, Verhoeff F. An analysis of anemia and child mortality. J Nutr 2001;131(2):636S-648S.

[4.] World Health Organization. Pocket book of Hospital Care for Children: Guidelines for the Management of Common Childhood Illnesses. 2nd ed. Geneva: WHO, 2013.

[5.] Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014;371(15):1381-1391.

[6.] Lackritz EM, Hightower AW, Zucker JR, et al. Longitudinal evaluation of severely anemic children in Kenya: The effect of transfusion on mortality and hematologic recovery. AIDS 1997;11(12):1487-1494. https://doi. org/10.1097/00002030-199712000-00013

[7.] Lacroix J, Hebert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med 2007;356(16):1609-1619. http://doi. org/10.1056/nejmoa066240

[8.] Kneyber MCJ, Hersi MI, Twisk JWR, Markhorst DG, Plotz FB. Red blood cell transfusion in critically ill children is independently associated with increased mortality. Intensive Care Med 2007;33(8):1414-1422. s00134-007-0741-9

[9.] Istaphanous GK, Wheeler DS, Lisco SJ, Shander A. Red blood cell transfusion in critically ill children: A narrative review. Pediatr Crit Care Med 2011;12(2):174183.

[10.] Lacroix J, Demaret P, Tucci M. Red blood cell transfusion: Decision making in pediatric intensive care units. Semin Perinatol 2012;36(4):225-231. https://doi. org/10.1053/j.semperi.2012.04.002

[11.] Carson JL. Red blood cell transfusion: A clinical practice guideline from the AABB. Ann Intern Med 2012;157(1):49-58.

[12.] Corwin HL, Gettinger A, Pearl RG, et al. The CRIT study: Anemia and blood transfusion in the critically ill - current clinical practice in the United States. Crit Care Med 2004;32(1):39-52. ccm.0000104112.34142.79

[13.] Akyildiz B, Ulgen Tekerek N, Pamukcu O, et al. Comprehensive analysis of liberal and restrictive transfusion strategies in pediatric intensive care unit. J Trop Pediatr 2018;64(2):118-125.

[14.] Ala F, Allain J-P, Bates I, et al. External financial aid to blood transfusion services in sub-Saharan Africa: A need for reflection. PLoS Med 2012;9(9):e1001309.

[15.] Kirpalani H, Whyte RK, Andersen C, et al. The Premature Infants in Need of Transfusion (PINT) study: A randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J Pediatr 2006;149(3):301-307. jpeds.2006.05.011

[16.] Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012;4:CD002042.

[17.] Goel R, Cushing MM, Tobian AAR. Pediatric patient blood management programs: Not just transfusing little adults. Transfus Med Rev 2016;30(4):235241.

[18.] Cazares-Benito MA, Cazares-Tamez R, Perez-Chavez F, et al. Impact on costs related to inadequate indication of blood transfusion. Medicina Universitaria 2016;18(72):148-152.

[19.] Harrison MC, Pillay S, Joolay Y, et al. Resource implications of adopting a restrictive neonatal blood transfusion policy. S Afr Med J 2013;103(12):916917.

[20.] Klaus SA, Frank SM, Salazar JH, et al. Hemoglobin thresholds for transfusion in pediatric patients at a large academic health center. Transfusion 2015;55(12):2890-2897.

[21.] Wise R. Saving blood, saving lives--an innovative rational blood utilization project. World Hosp Health Serv 2017;53(1):23-25.

[22.] Lackritz EM, Campbell CC, Ruebush TK, Hightower AW, Wakube W, Were JBO. Effect of blood transfusion on survival among children in a Kenyan hospital. Lancet 1992;340(8818):524-528.

[23.] English M, Ahmed M, Ngando C, Berkley J, Ross A. Blood transfusion for severe anaemia in children in a Kenyan hospital. Lancet 2002;359(9305):494495.

Accepted 25 May 2018.

P B S Radebe, MBChB, DCH, FC Paed (SA); P M Jeena, MBChB, FC Paed (SA), Cert Paed Pulmonology, PhD

Department of Paediatrics and Child Health, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

Corresponding author: P B S Radebe (

Caption: Fig. 1. Profile of the study population.
Table 1. Baseline characteristics of study population categorised
according to transfusion strategy (N=118)

                            Modified liberal strategy (n=68), n (%)

                            strategy (n=27),   Haemodynamically
Characteristics             n (%)              stable (n=47), n (%)

Age (months), mean (range)  13.9 (1 - 120)     11.6 (0.3 - 120)
Male                        17(63)             25 (53.2)
HIV infected                7 (25.9)           8 (17)
No. of days prior to
transfusion, mean (range)   5.3 (0 - 35)       3 (0 - 29)
No. of transfusions, mean
(range)                     1.1 (1 - 2)        1 (1 - 3)
PIM score, mean (range)     13.6 (0.4 - 96.9)  9.9 (0.5 - 68.8)
Primary diagnoses
 Respiratory diseases       9 (33.3)           14 (29.8)
 HIV/AIDS                   6 (22.2)           8 (17)
 Cardiac diseases           1 (3.7)            12 (25.5)
 Sepsis                     1 (3.7)            4 (8.5)
 Other                      10 (37)            9 (19.1)
Secondary diagnoses
 Respiratory diseases       15 (55.6)          19 (40.4)
 Sepsis                     4 (14.8)           10 (21.3)
 CNS                        1 (3.7)            6 (14.6)
 Cardiac                    0 (0)              1 (2.1)
 Other                      6 (22.2)           8 (17)
None                        1 (3.7)            3 (6.4)

                            unstable (n=21),
                            n (%)              Total (n=68)

Age (months), mean (range)  18.8 (0.16 - 144)  11.4 (0.16 - 144)
Male                        11 (52.4)          36 (52.9)
HIV infected                4 (19)             12 (17.7) *
No. of days prior to
transfusion, mean (range)   3(1 - 16)          5 (0 - 29)
No. of transfusions, mean
(range)                     1 (1 - 5)          1.4 (1 - 5) *
PIM score, mean (range)     13.7 (0.0 - 78.2)  11.1 (0.0 - 78.20)
Primary diagnoses
 Respiratory diseases       5 (23.8)           19 (27.9)
 HIV/AIDS                   4 (19)             12 (17.7) *
 Cardiac diseases           5 (23.8)           17 (25)
 Sepsis                     2 (9.5)            6 (8.8)
 Other                      5 (23.8)           14 (20.6)
Secondary diagnoses
 Respiratory diseases       7 (33.3)           26 (38.2)
 Sepsis                     4 (19)             14 (20.6)
 CNS                        0 (0)              6 (8.8)
 Cardiac                    1 (5)              2 (2.9)
 Other                      7 (33.3)           15 (22.1)
None                        2 (9.5)            5 (7.4)

                            Mixed strategy
                            (n=23)             p-value

Age (months), mean (range)  8.8 (1 - 108)      Ns
Male                        12 (52.2)          Ns
HIV infected                11 (47.8) *        0.02
No. of days prior to
transfusion, mean (range)   5.9 (1 - 18)       Ns
No. of transfusions, mean
(range)                     2.9 (2 - 6) *      0.001
PIM score, mean (range)     17.9 (0.4 - 42.1)  Ns
Primary diagnoses
 Respiratory diseases       6 (26.1)           Ns
 HIV/AIDS                   11 (47.8) *        0.02
 Cardiac diseases           0 (0)
 Sepsis                     2 (8.7)            Ns
 Other                      4 (17.4)           Ns
Secondary diagnoses
 Respiratory diseases       12 (52.2)          Ns
 Sepsis                     0 (0)              Ns
 CNS                        2 (8.7)            Ns
 Cardiac                    2 (8.7)            Ns
 Other                      6 (26.1)           Ns
None                        1 (4.4)            Ns

PIM = paediatric index of mortality; CNS =central nervous system;
Ns = not significant.

* p<0.05

Table 2. Physiological effects associated with different
transfusions (N-183)

                                                      ML: Total (b)
                                   Restrictive (a)
Parameters                         (n=64; 35%)        (n=119; 65%)

Pretransfusion                     6.4 (4 - 7)        8.3 (7.1 - 12)
haemoglobin (g/dL),
mean (range)
Relative difference in parameters
  post transfusion, %
 Haemoglobin (g/dL),
 mean (range)                      3.8 (2.04)             2.3 (2.73)
 P/F [O.sub.2] ratio <300          0                        6.20
 Heart rate                        -1.60                   -1.68
 Positive blood culture            25                     -21.43
 Temperature instability           -3.39                   -4.51
 Procalcitonin                     -2.33 *                  5.06
 White blood cell                  0                       12.28
 Hypotension                       -4.76 ([dagger])        -6.80
 Change in inotrope                -3.40 ([section])      -11.21
 Creatinine                        -4.76 ([double
                                      dagger])              3.81
 Urine output                      -3.40                   -1.20
 Platelets                         0                        5.20
 International ratio               -25                       -20
 Bilirubin                         13.63                     --
 Lactate                           -9.10                    3.80

                                   ML:                Haemodynamically
                                   Haemodynamically   unstable (d)
                                   stable (c)         (n=34; 28.6%)
                                   (n=85; 71.4%)

Pretransfusion                     8.3 (7.1 - 12)     8.5 .(1 - 10.5)
haemoglobin (g/dL),
mean (range)
Relative difference in parameters
  post transfusion, %
 Haemoglobin (g/dL),
 mean (range)                      2.6 (2.6)          1.6 (3.0)
 P/F [O.sub.2] ratio <300          -3.40              -13.70
 Heart rate                        -2.30              0.00
 Positive blood culture            -22.20             -20.00
 Temperature instability           -4.88              -3.50
 Procalcitonin                     1.79               13.00 *
 White blood cell                  12.20              12.50
 Hypotension                       9.40 ([dagger])    -48.50 ([dagger])
 Change in inotrope                1.20               -41.20
 Creatinine                        20.00 *            17.30 ([double
 Urine output                      0.00               0.00
 Platelets                         3.70               9.40
 International ratio               0                  -50
 Bilirubin                         --                 --
 Lactate                           5.50               4

                                         p-value (a
                                          v. b)

haemoglobin (g/dL),
mean (range)
Relative difference in parameters
  post transfusion, %
 Haemoglobin (g/dL),
 mean (range)                           0.0001
 P/F [O.sub.2] ratio <300                 0.4
 Heart rate                               0.9
 Positive blood culture                   0.2
 Temperature instability                  0.8
 Procalcitonin                            0.3
 White blood cell                         0.1
 Hypotension                              0.8
 Change in inotrope                       0.1
 Creatinine                               0.9
 Urine output                             0.6
 Platelets                                0.3
 International ratio                      0.9
 Bilirubin                                --
 Lactate                                 0.14

P/F = partial pressure of arterial oxygen/fractional supply of
oxygen; ML = modified liberal.

([dagger]) a v. c: p=0.02; ([double dagger]) a v. c: p=0.0001;
([section]) a v. c: p=0.008; ([paragraph]) a v. d: p=0.04; a
v. ([parallel]) d: p<0.001.

Table 3. Clinical outcomes of patients (N=118) in the
different transfusion strategy groups

                            Modified liberal (b)

Outcomes                    Restrictive (a)    Stable (n=47)
Duration of
mechanical                  8.6 (0 - 35) *     10.9 (0 - 50)
ventilation (days),
mean (range)

PICU stay (days),           10.8 (2 - 38)      12.9 (4 - 63)
mean (range)                ([dagger])

Mortality in PICU (N=118),
n (%)                       3 (11.1)           10 (21.3)

                            Modified liberal (b)

                            Unstable (n=21)     Total (n=68)

Duration of                 10.8 (2 - 42)      10.9 (0 - 50) *
ventilation (days),
mean (range)
                            13.9 (2 - 50)      13.2 (2 - 63)
PICU stay (days),
mean (range)

Mortality in PICU           9 (42.9)           19 (27.9)
(N=118), n (%)

                            Mixed (c) (n=23)   p-values
Duration of                                    c v. a: p<0.001
mechanical                  20.8 (6 - 48)      c v. b: p<0.001
ventilation (days),                            c v. d: p<0.001
mean (range)                                   c v. e: p<0.001
                                               c v. a: p<0.001
PICU stay (days),           23.9 (12 - 47)     c v. b: p<0.001
mean (range)                ([dagger])         c v. d: p<0.001
                                               c v. e: p<0.001
Mortality in PICU                              a v. e: p<0.02
(N=118), n (%)              13 (56.5)          d v. c: p=0.004
                                               b v. c: p=0.002

* a v. b: p>0.05

([dagger]) v d: p>0.05

PICU = paediatric intensive care unit.

Table 4A. Costing variables and subsequent costs associated
with different transfusions (N=183)

Costing variables           Restrictive
                            (n=64; 35%)     Haemodynamically stable
                                               (n=85; 46.4%)

Timing of decision to
  transfuse, n (%)
 Day                           53 (82.8)            71 (84)
 Night *                        6 (9.4)             6 (7.1)
 Unknown                        5 (7.8)              8 (9)
Transfusion time
 Day                           27 (42.2)           31 (36.5)
 Night                         37 (57.8)           54 (63.5)
 Units transfused                  74                  93
Total transfusion cost **     R119 065.94         R155 280.15

                            Modified liberal
                            Haemodynamically    Total (n=119; 65%)
                            (n=34; 18.6%)
Costing variables

Timing of decision to
  transfuse, n (%)
 Day                            27 (79)            98 (82.4)
 Night *                        3 (8.8)             9 (7.6)
 Unknown                         4 (12)            12 (10.1)
Transfusion time
 Day                           19 (55.9)            50 (42)
 Night                         15 (44.1)            69 (58)
 Units transfused                  39                 132
Total transfusion cost **      R70 148.46         R225 428.61

* Defined as any transfusion that occurred between 18h00 and 08h00 on
weekdays, and between 13h00 on Saturday and 08h00 on Monday.

** Transfusion cost is calculated as the sum of the unit cost per
transfusion pack (R1 485.65) and the levies raised for typing and
screening (R320.31) and cross-matching (R715.29 for routine
cross-matching; R134.78 for emergency cross-matching),
as shown in Table 4B.

Table 4B. Levies associated with transfusion decisions (N=183)

                                             Modified liberal

Levy description          Restrictive       Haemodynamically stable
                                            (n=85; 46.4%)
                          (n=64; 35%)
 Routine cross-match      R2 861.16         R4 291.74
 Emergency cross-match    R1 213.02         R1 617.36
 Unnecessary after-hours  26 (40.6)         40 (47)
transfusion, n (%)
 After-hours levy *       R9 397.40         R14 457.60
 Type and screen          R640.62           R960.93

                          Modified liberal
                          Haemodynamically  Total (n=119;
                          unstable (n=34;     65%)

 Routine cross-match      R1 430.58         R5 722.32
 Emergency cross-match    R1 347.80         R2 965.16
 Unnecessary after-hours  8 (23.5)          48 (40.3)
transfusion, n (%)
 After-hours levy *       R2 891.50         R17 349.10
 Type and screen          R640.62           R1 601.55

* Per transfusion: R361.44.
COPYRIGHT 2018 Health & Medical Publishing Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Radebe, P.B.S.; Jeena, P.M.
Publication:South African Journal of Child Health
Article Type:Report
Geographic Code:6SOUT
Date:Dec 1, 2018
Previous Article:Universal newborn hearing screening in public healthcare in South Africa: Challenges to implementation.
Next Article:Enteric pathogen co-infections in the paediatric population from rural communities in the Vhembe District, South Africa.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |